Angie Loreen Zaklan, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 15419 Avenue 96, Pixley, CA 93256 Phone: 559-901-8513 |
News Archive
Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.
Nektar Therapeutics today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in healthy subjects.
MitoSciences Inc. today announces that it has been awarded a $244,000 grant under the IRS Qualifying Therapeutic Discovery Project. This award was made in support of MitoSciences' efforts to develop the world's most advanced set of assays for unlocking the role of metabolism in cancer and other critical diseases, and for helping researchers to design and monitor the most effective therapies for those conditions.
Selective targeting of the neurotransmitter that differentially affects brain cells that control the two distinct functions of the pancreas may allow for new medication therapies for conditions like diabetes, dyspepsia and gastro-esophageal reflux, according to Penn State College of Medicine researchers.
› Verified 3 days ago